A Phase 2 interventional study of Apalutamide and Biopsy in Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by University of Washington · Phase 2, Interventional, and Treatment
The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 4 that started in 2024, is one of 37 in phase 2, and was the 66th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
34 studies in Prostatic Neoplasms by University of Washington: 7 open now, 8 under way, none of them phase 3. Of 25 finished, 15 (60%) have results posted.
Among the 34 studies in Prostatic Neoplasms by University of Washington, this one is the 23rd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 21 in phase 2, and was the 30th registered.
University of Washington’s Prostatic Neoplasms studies by the year they started, since 1997.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among University of Washington’s 34 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may work better in treating patients with castration-resistant prostate cancer.
OUTLINE:
Patients receive golimumab subcutaneously (SC) every 4 weeks for 6 doses and apalutamide orally (PO) daily. Treatment with apalutamide continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo computed tomography (CT) scans or magnetic resonance imaging (MRI), prostate-specific membrane antigen (PSMA) positron emission tomography (PET), bone scan, and collection of blood samples throughout the study.
After completion of study treatment, patients are followed every 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Uncontrolled or active infection, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive golimumab SC every 4 weeks for 6 doses and apalutamide PO daily. Treatment with apalutamide continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo CT scans or MRI, PSMA PET, bone scan, and collection of blood samples throughout the study.
Drug: Apalutamide · Procedure: Biopsy · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Golimumab · Procedure: Magnetic Resonance Imaging · Procedure: PSMA PET Scan · Procedure: Bone Scan
Given PO
Also known as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927
Undergo tumor biopsy
Also known as: BIOPSY_TYPE, Bx
Undergo collection of blood samples
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo CT scan
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography
Given SC
Also known as: CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer
Undergo MRI
Also known as: Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging
Undergo PSMA PET
Also known as: Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography
Undergo bone scan
Also known as: Bone Scintigraphy
Prostate Specific Antigen (PSA)50 Response Rate
Defined by at least a 50% decline in PSA from baseline, in subjects with castrate resistant prostate cancer after combination treatment with TNF-alpha alpha blockade (golimumab) and AR antagonism (apalutamide).
Time frame: Up to 12 weeks
Objective Response Rate
Will determine objective response rate of measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria for soft tissue metastases. Target Lesions were assessed as follows: CR: Disappearance of all target lesions. All pathological lymph nodes short axis reduced to \<10 mm. PR: Decrease by ≥30% in the sum of diameters. PD: Increase by ≥20% in the sum of diameters with an absolute increase of ≥5 mm, or appearance of ≥1 new lesion. SD: Neither sufficient shrinkage for PR nor sufficient increase for PD. Non-Target Lesions were assessed as follows: CR: Disappearance of all non-target lesions, normalization of tumor markers, and all lymph nodes must be non-pathologic in size (\<10 mm short axis). Non-CR/Non-PD: Persistence of ≥1 non-target lesion and/or maintenance of tumor marker level above the normal limits. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: Up to 14.5 months
Radiographic Progression Free Survival (PFS)
The duration of radiographic PFS (rPFS) will be calculated for all treated subjects with soft tissue and/or bone disease as the time from the first dose of IP to the first objective evidence of radiographic progression or death from any cause, whichever occurs first. Radiographic disease progression is defined as progressive disease by RECIST for soft tissue and PCWG3 for bone disease. The PFS will be estimated using the Kaplan-Meier method for the treated population.
Time frame: Up to 14.5 months
PSA PFS
The interval between enrollment and the date of documented PSA progression. Progression will be declared if patient has documented to have a testosterone less than 50 ng/dL. In cases where a testosterone level has not been obtained and patient has not had an orchiectomy, progressive disease will be deemed if patient had a documented rise in PSA on luteinizing hormone-releasing hormone analogue therapy. Progression free survival curves will be generated using Kaplan-Meier method.
Time frame: Up to 14 months
PSA Doubling Time
The rate of PSA doubling will be calculated from nadir to confirmed PSA progression after 2 subsequent rises 1 week apart using standard calculators
Time frame: Up to 14 months
Time to Subsequent Antineoplastic Therapy
The interval between enrollment and the date of documented initiation of next therapy.
Time frame: Up to 16 months
Incidence of Adverse Events
Assess the incidence and severity of adverse events according to the National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0.
Time frame: Up to 30 days after final receipt of golimumab and/or apalutamide (up to 15 months)
| Milestone | Treatment (Golimumab, Apalutamide) |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
Defined by at least a 50% decline in PSA from baseline, in subjects with castrate resistant prostate cancer after combination treatment with TNF-alpha alpha blockade (golimumab) and AR antagonism (apalutamide).
| Participants | Treatment (Golimumab, Apalutamide) |
|---|---|
| Number of Subjects who had a PSA50 response | 0 |
| Number of Subjects who did not have a PSA50 response | 8 |
Will determine objective response rate of measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria for soft tissue metastases. Target Lesions were assessed as follows: CR: Disappearance of all target lesions. All pathological lymph nodes short axis reduced to \<10 mm. PR: Decrease by ≥30% in the sum of diameters. PD: Increase by ≥20% in the sum of diameters with an absolute increase of ≥5 mm, or appearance of ≥1 new lesion. SD: Neither sufficient shrinkage for PR nor sufficient increase for PD. Non-Target Lesions were assessed as follows: CR: Disappearance of all non-target lesions, normalization of tumor markers, and all lymph nodes must be non-pathologic in size (\<10 mm short axis). Non-CR/Non-PD: Persistence of ≥1 non-target lesion and/or maintenance of tumor marker level above the normal limits. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
| Participants | Treatment (Golimumab, Apalutamide) |
|---|---|
| Number of Subjects who had an objective response | 0 |
| Number of Subjects who did not have an objective response | 5 |
The duration of radiographic PFS (rPFS) will be calculated for all treated subjects with soft tissue and/or bone disease as the time from the first dose of IP to the first objective evidence of radiographic progression or death from any cause, whichever occurs first. Radiographic disease progression is defined as progressive disease by RECIST for soft tissue and PCWG3 for bone disease. The PFS will be estimated using the Kaplan-Meier method for the treated population.
| Months | Treatment (Golimumab, Apalutamide) |
|---|---|
| Radiographic Progression Free Survival (PFS) | 2.83 (2.7 to NA) |
The interval between enrollment and the date of documented PSA progression. Progression will be declared if patient has documented to have a testosterone less than 50 ng/dL. In cases where a testosterone level has not been obtained and patient has not had an orchiectomy, progressive disease will be deemed if patient had a documented rise in PSA on luteinizing hormone-releasing hormone analogue therapy. Progression free survival curves will be generated using Kaplan-Meier method.
| Months | Treatment (Golimumab, Apalutamide) |
|---|---|
| PSA PFS | 3.62 (2 to NA) |
The rate of PSA doubling will be calculated from nadir to confirmed PSA progression after 2 subsequent rises 1 week apart using standard calculators
| Months | Treatment (Golimumab, Apalutamide) |
|---|---|
| PSA Doubling Time | 2.8 (0.7 to 6.9) |
The interval between enrollment and the date of documented initiation of next therapy.
| Months | Treatment (Golimumab, Apalutamide) |
|---|---|
| Time to Subsequent Antineoplastic Therapy | 4.8 (3.8 to NA) |
Assess the incidence and severity of adverse events according to the National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0.
| Participants | Treatment (Golimumab, Apalutamide) |
|---|---|
| Number of Subjects who experienced an AE of any grade related to study therapy | 7 |
| Number of Subjects who did not experience an AE of any grade related to study therapy | 1 |
| Number of Subjects who experienced a Grade 3 adverse event | 3 |
| Number of Subjects who did not experience a Grade 3 adverse event | 5 |
| Number of Subjects who had a Grade 4 or Grade 5 adverse event | 0 |
Collected over AEs will be monitored and recorded in study-specific case report forms (CRFs) from time a subject has signed and dated an Informed Consent Form (ICF) until 30 days after the last documented use of the product under study within the study, up to 15 months total.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (Golimumab, Apalutamide) | 1/8 (12.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Event | Treatment (Golimumab, Apalutamide) |
|---|---|
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/8 |
| PurpuraSkin and subcutaneous tissue disorders | 1/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/8 |
| UrticariaSkin and subcutaneous tissue disorders | 1/8 |
| Event | Treatment (Golimumab, Apalutamide) |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/8 |
| AnorexiaMetabolism and nutrition disorders | 2/8 |
| Maculopapular RashSkin and subcutaneous tissue disorders | 2/8 |
| FatigueGeneral disorders | 2/8 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/8 |
| Hair LossSkin and subcutaneous tissue disorders | 2/8 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/8 |
| BursitisMusculoskeletal and connective tissue disorders | 1/8 |
| DiverticulitisGastrointestinal disorders | 1/8 |
| PurpuraSkin and subcutaneous tissue disorders | 1/8 |
| Age, Categorical(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 6 |
| Sex: Female, Male(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| Female | 0 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Treatment with prior NHT (novel hormone therapy)(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| Abiraterone | 2 |
| Enzalutamide | 5 |
| Darolutamide | 1 |
| Apalutamide | 0 |
| Prior taxane therapies(Participants) | Treatment (Golimumab, Apalutamide) |
|---|---|
| Received taxane chemotherapy | 0 |
| Has not received taxane chemotherapy | 8 |
| Baseline PSA(ng/mL) | Treatment (Golimumab, Apalutamide) |
|---|---|
| Subject 1 | 2.48 |
| Subject 2 | 3.38 |
| Subject 3 | 1.04 |
| Subject 4 | 6.18 |
| Subject 5 | 123.76 |
| Subject 6 | 7.81 |
| Subject 7 | 2.71 |
| Subject 8 | 44.72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2024 to primary completion in Jul 2025, 14 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Apr 2026, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apalutamide · Golimumab